BridgeBio Pharma stock has delivered a 149.6% return over the past three years, yet its valuation checks lean expensive and suggest the recent strength may already price in a lot of good news. With the company now highlighting a potential blockbuster opportunity around its encaleret program, investors are weighing strong share price gains against a weaker value score.

• BridgeBio Pharma has returned 149.6% over three years, which puts extra focus on whether the current share price still offers an appealing entry point.
• The FDA acceptance of the New Drug Application for encaleret and the planned expansion into broader indications may support high expectations, while regulatory and clinical execution risk can still affect what investors are willing to pay today.
• On Simply Wall St's broader valuation checks, BridgeBio Pharma scores 2 out of 6, which points to a stock that currently leans expensive rather than a clear bargain.

For investors, the debate is whether BridgeBio Pharma's ongoing drug pipeline progress is enough to justify paying up after such a strong multi year run.

Is BridgeBio Pharma Getting Expensive on Sales?

P/S can be useful for a business like BridgeBio Pharma where earnings and free cash flow are still affected by heavy research spending. On this measure, BridgeBio trades at a P/S of 28.9x, compared with a Biotechs industry average of 11.0x and a peer average of 18.2x. That is a clear premium to the wider group of biotech stocks.

The fair P/S ratio for BridgeBio, based on its profile and risks, is estimated at 23.3x. The current 28.9x level sits well above that, which points to a stock that already embeds optimistic expectations for future revenue from encaleret and the broader pipeline, even with the recent FDA acceptance of the NDA in mind.

On the P/S multiple, BridgeBio Pharma stock currently appears expensive relative to both tailored and industry benchmarks.

The BridgeBio Pharma Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the BridgeBio Pharma valuation puzzle leaves off. They explain which assumptions about BridgeBio Pharma's future revenue growth, margins and earnings would need to hold for the stock to be worth materially more or less than it is today. Each one is framed as a thesis about the business that you can track over time on the company’s Community page.

Community views on BridgeBio Pharma sit far apart, from a rare disease launch wave thesis to concerns that competition and costs are already fully reflected.

Bull case: 19% undervalued

"Established commercial and patient support infrastructure, enabled by strong sales execution and white-glove access models, is expected to be redeployed for future launches, reducing incremental fixed costs per new product and supporting long-term operational leverage and net margin expansion…"

Bear case: 242% overvalued

"With Amvuttra’s recent blockbuster HELIOS-B Phase 3 data, the ATTR-CM landscape is aggressively shifting from TTR stabilizers to TTR silencers…"

Do you think there's more to the story for BridgeBio Pharma? Head over to our Community to see what others are saying!

The Bottom Line

BridgeBio Pharma now trades on multiples that point to an overvalued stock on sales-based measures, especially against both peers and a tailored benchmark. That does not end the debate, but it raises the bar for what the encaleret launch and wider pipeline need to deliver to keep the current pricing intact. The key question from here is whether future revenue and margin progress can catch up to the premium investors are already paying, or whether the valuation starts to look stretched if execution or market uptake fall short.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.